Why the study?
To evaluate the hospital resource utilization, costs, and 1-month readmissions among patients hospitalized for venous thromboembolism treated with warfarin versus apixaban.
Does apixaban reduce hospital resource utilization, costs, and 1-month readmissions compared to warfarin in patients hospitalized for venous thromboembolism?
Does apixaban reduce hospital resource utilization, costs, and 1-month readmissions compared to warfarin in patients hospitalized for venous thromboembolism?
In a real-world US cohort of patients hospitalized for VTE, apixaban was associated with shorter hospital stays, lower index hospitalization costs, and fewer bleeding-related readmissions at 1 month compared to warfarin.
Answers are grounded in this paper and cite their sources.
Apixaban was associated with lower VTE hospitalization costs than warfarin; leaves open whether findings warrant practice change pending prospective data.
A real-world US database analysis was conducted to evaluate the hospital resource utilization and costs of patients hospitalized for venous thromboembolism (VTE) treated with warfarin versus apixaban. Additionally, 1-month readmissions were evaluated. Of 28 612 patients with VTE identified from the Premier Hospital database (August 2014-May 2016), 91% (N = 26 088) received warfarin and 9% (N = 2524) received apixaban. Outcomes were assessed after controlling for key patient/hospital characteristics. For index hospitalizations, the average length of stay (LOS) was longer (3.8 vs 3.1 days, P < .001; difference: 0.7 days) and mean hospitalization cost higher (US$3224 vs US$2,740, P < .001; difference: US$484) for warfarin versus apixaban-treated patients. During the 1-month follow-up period, warfarin treatment was associated with a greater risk of all-cause readmission (odds ratio [OR]: 1.27; 95% confidence interval [CI]: 1.09-1.48, P = .003), major bleeding (MB)-related readmission (OR: 2.10; 95% CI: 1.03-4.27, P = .04), and any bleeding-related readmission (OR: 1.67; 95% CI: 1.09-2.56, P = .02) versus apixaban. The results of this real-world analysis show that compared to warfarin, apixaban treatment was associated with shorter index hospital stays, lower index hospitalization costs, and reduced risk of MB-related readmissions among hospitalized patients with VTE.
No takes yet. Share an insight, caveat, or question.
Deitelzweig et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: